(CYCC) Cyclacel - Performance -74.3% in 12m
Compare CYCC with Indices, Sectors and Commodities and Bonds. Who performs better in which timeframe?
Performance Rating
-93.23%
#192 in Group
Rel. Strength
4.55%
#7618 in Universe
Total Return 12m
-74.32%
#154 in Group
Total Return 5y
-99.13%
#184 in Group
P/E -
(?) Percentile in Group
P/E Forward -
(?) Percentile in Group
PEG -
(?) Percentile in Group
FCF Yield -18.27%
(?) Percentile in Group
12m Total Return: CYCC (-74.3%) vs XBI (-1.8%)

5y Drawdown (Underwater) Chart

Top Performers in Biotechnology
Overall best picks of Peer Group Selected by proven GARP Predictive Metrics, sorted by Growth Rating
Symbol | 1m | 12m | 5y | P/E | P/E Forward | PEG | EPS Stability |
EPS CAGR |
---|---|---|---|---|---|---|---|---|
UTHR NASDAQ United Therapeutics |
-1.68% | 29.3% | 171% | 12.1 | 10.6 | 1.43 | 81.5% | 18.5% |
HLN NYSE Haleon |
-0.23% | 21% | 41.1% | 24.4 | 20.2 | 1.79 | 64.4% | 6.58% |
AMGN NASDAQ Amgen |
-6.62% | 9.44% | 46.9% | 37 | 13.4 | 0.94 | -42.0% | -25.9% |
LONN SW Lonza |
8.56% | 16.2% | 38.7% | 60.7 | 31.7 | 1.15 | 12.6% | -10.3% |
BIM PA Biomerieux |
3.94% | 19.8% | 8.84% | 31 | 24.2 | 1.45 | -58.7% | -25.1% |
NBIX NASDAQ Neurocrine Biosciences |
-2.63% | -21.7% | 8.36% | 32.4 | 21.5 | 0.27 | 64.4% | 51.8% |
KMDA NASDAQ Kamada |
-2.12% | 27.5% | -10.6% | 26.6 | 24 | 0.96 | 80.4% | 43% |
ERF PA Eurofins Scientific SE |
14% | -1.49% | 17.2% | 26.6 | 13.6 | 0.56 | -67.4% | -17.7% |
Performance Comparison: CYCC vs XBI vs S&P 500
XBI (SPDR S&P Biotech ETF) is the Sector Benchmark for CYCC
Total Return (including Dividends) | CYCC | XBI | S&P 500 |
---|---|---|---|
1 Month | 95.02% | 2.28% | -0.87% |
3 Months | 63.52% | -10.48% | -7.58% |
12 Months | -74.32% | -1.83% | 11.88% |
5 Years | -99.13% | -12.72% | 110.33% |
Trend Score (consistency of price movement) | CYCC | XBI | S&P 500 |
1 Month | 39.2% | 56.6% | 23% |
3 Months | -70.0% | -89.3% | -88.5% |
12 Months | -96.7% | -42.4% | 55.1% |
5 Years | -94.7% | -53.6% | 84.1% |
Relative Strength (compared with Indexes) | Rank in Peer Group | vs. XBI | vs. S&P 500 |
1 Month | #2 | 90.7% | 96.7% |
3 Month | #6 | 82.7% | 76.9% |
12 Month | #153 | -73.8% | -77.0% |
5 Years | #184 | -99.0% | -99.6% |
FAQs
Does CYCC Cyclacel outperforms the market?
No,
over the last 12 months CYCC made -74.32%, while its related Sector, the SPDR S&P Biotech (XBI) made -1.83%.
Over the last 3 months CYCC made 63.52%, while XBI made -10.48%.
Over the last 3 months CYCC made 63.52%, while XBI made -10.48%.
Performance Comparison CYCC vs Indeces and Sectors
CYCC vs. Indices CYCC is Over or Underperforming
Symbol | 1w | 1m | 6m | 12m | |
---|---|---|---|---|---|
US S&P 500 | SPY | 133% | 95.9% | -14.3% | -86.2% |
US NASDAQ 100 | QQQ | 132% | 93.6% | -14.7% | -87.0% |
US Dow Jones Industrial 30 | DIA | 134% | 98.2% | -14.2% | -83.5% |
German DAX 40 | DAX | 134% | 93.7% | -33.8% | -99.0% |
Shanghai Shenzhen CSI 300 | CSI 300 | 137% | 97.8% | -11.3% | -80.3% |
Hongkong Hang Seng | HSI | 134% | 95.0% | -16.2% | -88.2% |
India NIFTY 50 | INDA | 136% | 91.0% | -14.5% | -77.4% |
Brasil Bovespa | EWZ | 134% | 90.4% | -18.0% | -68.5% |
CYCC vs. Sectors CYCC is Over or Underperforming
Symbol | 1w | 1m | 6m | 12m | |
---|---|---|---|---|---|
Communication Services | XLC | 133% | 96.1% | -20.4% | -98.3% |
Consumer Discretionary | XLY | 133% | 95.1% | -16.8% | -87.6% |
Consumer Staples | XLP | 136% | 94.8% | -19.6% | -85.5% |
Energy | XLE | 137% | 109% | -8.46% | -63.2% |
Financial | XLF | 134% | 97.1% | -21.9% | -97.0% |
Health Care | XLV | 133% | 98.8% | -12.6% | -76.0% |
Industrial | XLI | 132% | 94.9% | -15.0% | -83.9% |
Materials | XLB | 133% | 97.5% | -6.84% | -70.8% |
Real Estate | XLRE | 134% | 96.3% | -13.4% | -92.4% |
Technology | XLK | 130% | 93.3% | -10.9% | -82.1% |
Utilities | XLU | 136% | 95.0% | -16.4% | -96.2% |
Aerospace & Defense | XAR | 132% | 88.6% | -27.8% | -101% |
Biotech | XBI | 132% | 92.7% | -1.61% | -72.5% |
Homebuilder | XHB | 134% | 97.3% | 0.56% | -67.3% |
Retail | XRT | 134% | 95.6% | -8.68% | -71.6% |